Michael Wechsler, MD
BRIGHAM AND WOMEN'S HOSPITAL
Michael Wechsler, MD, is an Associate Physician in the Pulmonary and Critical Care Division of Brigham and Women's Hospital in Boston and is on the faculty at Harvard Medical School. He is a member of the Steering Committee of the NIH's Asthma Clinical Research Network and is active in both basic and clinical research focused on asthma and allergies. Dr. Wechsler is clinically active in the intensive care unit practicing critical care medicine. His scientific interests include the genetics of asthma, Churg-Strauss syndrome, and eosinophilia. Dr. Wechsler has received research awards from the NIH, American Lung Association, the ACCP's Chest Foundation, and from Merck and GlaxoSmithKline. He has published both clinical and research manuscripts in NEJM, JAMA, Lancet, Chest, the Journal of Asthma and Clinical Immunology, and the American Journal of Respiratory and Critical Care Medicine. Dr. Wechsler has consulted for Novartis, Genentech, Scoggin, and Metropolitan Capital. (This is me - Update Profile)
| 1996 - present | Associate Physician in Pulmonary and Critical Care BRIGHAM AND WOMEN'S HOSPITAL |
|---|
GLG Study Groups with Michael Wechsler, MD(?)
| Study Group Name | Members |
|---|---|
| Physicians who Treat Asthma (US) | 442 |
| Allergists (US) | 404 |
| Critical Care Physicians | 732 |
| Critical Care Physicians (US) | 344 |
GLG NewsSM Analyses by Michael Wechsler, MD(?)
Singulair helps millions of people suffering from asthma. While there are a few sporadic cases of suicide and depression among the millions of patients taking singulair, no causal link has been established and there is no clear mechanism of how singulair might even cause such effects. In fact,...
Zyflo is a great drug in its oral fornmaulation with goiod efficacy but has failed because one has to take it multiple times a day and because one has to monitor liver function. This new IV formulation should be as effective in the ER setting, but hurdles include poor drug marketing by Critical Therapeuitcs...
While these data seem to be good for medimmune, it is at least the third anti IL5 therapy that has been developed (others by GSK and Schering) . The others have been more extensively studied and if successful will more likely come to market sooner. Furthermore, while it is hoped to make a dent into...
GLG InstituteSM Seminars with Michael Wechsler, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Michael Wechsler, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms